Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Details Actions in Response to Shareholder Feedback
Has Held Several Discussions with WaterMill   to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional   Past of WaterMill Nominee   Holger Weis BOSTON , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology ,
View HTML
Toggle Summary Ziopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Ziopharm’s Board of Directors
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings R aise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON , Nov.
View HTML
Toggle Summary Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder Value
Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook Outlines Additions of Five Highly Qualified Industry Veteran s to Board   Over the Last 18 Months BOSTON , Nov. 20, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced
View HTML
Toggle Summary Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting
– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,  and a Confirmed Partial Response – – Updated Interim Data from Ongoing Phase 1 Study of Controlled IL-12 in Combination with Nivolumab Show a mOS of 16.9 Months
View HTML
Toggle Summary Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer
– Pharmaceutical Executive   with 2 0 + Year s of Experience   Across All Phases of Clinical Research Including IND Submission s , Trial Design and   Regulatory Filings – – Former Chief Medical Officer for Servier Pharmaceuticals ; Oncology R &D Leadership R oles at Shire, Pfizer   and Sanofi –
View HTML
Toggle Summary Ziopharm Oncology Appoints Mary Thistle to Board of Directors
– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director – – Biotechnology Leader with 25+ Year Track Record of Creating Shareholder Value Through Strategy, Business Development, Commercial and Financial Leadership – –   Scott
View HTML
Toggle Summary Ziopharm Oncology to Participate in Jefferies Virtual London Healthcare Conference on November 19, 2020
BOSTON , Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at
View HTML
Toggle Summary Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update
– Company plans to file IND for Ziopharm TCR-T program   in Q1   of next year for its  Library “hotspot” trial   – – Eden BioCell on track for IND filing i n Taiwan   for autologus CAR-T clinical trial this year based on rapid personalized manufacturing ; several patients dosed under compassionate
View HTML
Toggle Summary Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
Urges Shareholders to Sign and Return Ziopharm’s GREEN Consent Revocation Card Emphasizes that Substantial Board Refr eshment is Already in Process Reiterates Commitment to Implementing Strategy and Delivering Significant Value to S hareholders Questions WaterMill’s Attempt to Seize Outsize d
View HTML
Toggle Summary Ziopharm Oncology to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020
BOSTON , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended September 30, 2020
View HTML